Drugs / BNT165e
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06069544 | Nov 2023 → May 2025 | malaria | BioNTech SE | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNT165e | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06069544 ↗ |
| Modality | Vaccine | “The multi-antigen malaria vaccine (designated BNT165e)” NCT06069544 ↗ |
| Route | Intramuscular | “administered as intramuscular injection” NCT06069544 ↗ |